Denali Therapeutics (DNLI) News
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
18.45+0.25 (+1.37%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DNLI news summary
We found 7 recent headlines mentioning Denali Therapeutics (DNLI): 0 in the past week and 5 in the past 30 days, most often from Nasdaq, GlobeNewswire, Investing.com. For price context, DNLI is up 1.37% at $18.45. The most recent story, "DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?", was published by Nasdaq on Nov 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Denali Therapeutics headlines
- DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.NasdaqDNLI, BIIB, TAK
- Why is Denali Therapeutics stock surging today?Investing.com
- Denali Therapeutics Reports Third Quarter 2026 Financial ResultsDenali Therapeutics Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting net product revenue of $17.8 million for AVLAYAH in its second full commercial…Nasdaq
- Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsSOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2026, and provided…GlobeNewswire
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology ProductSOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH ® (tividenofusp alfa-eknm) has been recognized as the “Best…GlobeNewswire
- Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third…GlobeNewswire
- Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.NasdaqRARE, AMGN, DNLI